These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10612092)

  • 1. [The effect of large dose prednisone therapy on immunological markers in multiple sclerosis].
    Wender M; Losy J; Michałowska-Wender G; Kozubski W; Sosnowski P
    Neurol Neurochir Pol; 1999; 33(4):771-9. PubMed ID: 10612092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The early stage of multiple sclerosis in the light of molecular and immunological studies.
    Michałowska-Wender G
    Folia Neuropathol; 1999; 37(4):273-6. PubMed ID: 10705651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Urine free light chains kappa in multiple sclerosis].
    Michałowska-Wender G; Losy J; Tokarz-Kupczyk E; Wygladalska-Jernas H; Wender M
    Neurol Neurochir Pol; 1999; 33(2):311-9. PubMed ID: 10463246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of immunosuppressive therapy on humoral immune response in multiple sclerosis.
    Wajgt A; Górny M; Szczechowski L; Grzybowski G; Ochudło S
    Acta Med Pol; 1989; 30(3-4):121-8. PubMed ID: 2485126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [TNF-alpha and soluble TNF receptor p55 in patients wtih multiple sclerosis].
    Geppert A; Losy J
    Neurol Neurochir Pol; 1999; 33(4):807-14. PubMed ID: 10612095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of large-dose prednisone therapy on IgG subclasses in multiple sclerosis.
    Losy J; Michałowska-Wender G; Wender M
    Acta Neurol Scand; 1994 Jan; 89(1):69-71. PubMed ID: 8178632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of prednisone and azathioprine treatment on oligoclonal IGG in the cerebrospinal fluid of multiple sclerosis patients. Preliminary communication].
    Losy J; Karolewska J; Wender M
    Neurol Neurochir Pol; 1996; 30(2):201-11. PubMed ID: 8756247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis.
    Lamers KJ; Uitdehaag BM; Hommes OR; Doesburg W; Wevers RA; von Geel WJ
    J Neurol Neurosurg Psychiatry; 1988 Oct; 51(10):1334-7. PubMed ID: 2465387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunological markers of disease activity in the course of 2-CDA treatment of multiple sclerosis].
    Michałowska-Wender G; Tokarz-Kupczyk E; Losy J; Sniatała-Kamasa M; Wender M
    Neurol Neurochir Pol; 1999; 33(4):749-56. PubMed ID: 10612090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of alternating treatment of multiple sclerosis with encorton and levamisole on IgG synthesis within the cerebrospinal fluid spaces].
    Wender M; Michałowska G; Tokarz-Kupczyk E
    Neurol Neurochir Pol; 1988; 22(2):103-7. PubMed ID: 3405385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Myelin basic protein stimulation index of CD 2 cells in the course of steroid treatment].
    Wender M; Sniatała-Kamasa M; Wójcicka M; Tokarz-Kupczyk E; Losy J
    Neurol Neurochir Pol; 1999; 33(4):765-70. PubMed ID: 10612091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of high-dose prednisone medication on autoantibody specific activity and on circulating immune complex level in cerebrospinal fluid of multiple sclerosis patients.
    Wajgt A; Górny MK; Jenek R
    Acta Neurol Scand; 1983 Dec; 68(6):378-85. PubMed ID: 6666546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Neurological adverse events under anti-TNF alpha therapy].
    Cohen M; Baldin B; Thomas P; Lebrun C
    Rev Neurol (Paris); 2012 Jan; 168(1):33-9. PubMed ID: 22098827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis.
    Warren KG; Catz I; Johnson E; Mielke B
    Ann Neurol; 1994 Mar; 35(3):280-9. PubMed ID: 7510098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oligoclonal antibodies in the diagnosis of multiple sclerosis and other diseases of the nervous system].
    Losy J
    Neurol Neurochir Pol; 1991; 25(3):363-70. PubMed ID: 1961384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey.
    Seror R; Richez C; Sordet C; Rist S; Gossec L; Direz G; Houvenagel E; Berthelot JM; Pagnoux C; Dernis E; Melac-Ducamp S; Bouvard B; Asquier C; Martin A; Puechal X; Mariette X;
    Rheumatology (Oxford); 2013 May; 52(5):868-74. PubMed ID: 23287362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of ACTH therapy on IgG synthesis in cerebrospinal fluid spaces in patients with disseminated sclerosis].
    Wender M; Michałowska G; Wajgt A
    Neurol Neurochir Pol; 1986; 20(5):437-43. PubMed ID: 3035406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary free kappa light chain levels in chronic progressive multiple sclerosis.
    Constantinescu CS; Mehta PD; Rostami AM
    Pathobiology; 1994; 62(1):29-33. PubMed ID: 8031473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple sclerosis: effect of myelin basic protein on interleukin 1, interleukin 2 production and interleukin 2 receptor expression in vitro.
    Selmaj K; Nowak Z; Tchórzewski H
    Clin Exp Immunol; 1988 Jun; 72(3):428-33. PubMed ID: 2458871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Free kappa light chains in multiple sclerosis spinal fluid.
    Rudick RA; Pallant A; Bidlack JM; Herndon RM
    Ann Neurol; 1986 Jul; 20(1):63-9. PubMed ID: 3090930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.